ReviewIndian journal of ophthalmology
Bevacizumab: off-label use in ophthalmology.
Review in Indian journal of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01736449 (Role of Sub-Conjunctival Bevacizumab in Post Pterygium Excision Management), which is not on this map. Cited by 44 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Role of Sub-Conjunctival Bevacizumab in Post Pterygium Excision Management
Who cites it
44 citing papers in PubMed, 3 syntheses or guidelines pooled it, 86 citations in OpenAlex.
- Disease stability and extended dosing under anti-VEGF treatment of exudative age-related macular degeneration (AMD) - a meta-analysis.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2021Pooled it
- Real-world data in retinal diseases treated with anti-vascular endothelial growth factor (anti-VEGF) therapy - a systematic approach to identify and characterize data sources.BMC ophthalmology · 2019Pooled it
- Bevacizumab for ocular neovascular diseases: a systematic review.Sao Paulo medical journal = Revista paulista de medicina · 2009Pooled it
- Efficacy and safety of anti-VEGF monoclonal antibody 601 for macular oedema in retinal vein occlusion: two phase IIa randomised clinical trials.The British journal of ophthalmology · 2026Trial
- Repurposing biosimilars, rethinking costs: a framework for sustainable drug pricing for repurposed bevacizumab for intravitreal injections.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Indications and outcome of intravitreal bevacizumab injection in a Community Eye Hospital, Nepal.BMC ophthalmology · 2026Article
- Design and characterization of intravitreal bevacizumab-loaded PLGA nanoparticles: pharmacokinetic and biodistribution impact.Drug delivery and translational research · 2026Article
- Review
- Disproportionality analysis of off-label intravitreal bevacizumab in the FDA Adverse Event Reporting System database.Therapeutic advances in drug safety · 2026Article
- The landscape of antibody production systems: recombinant expression for research, diagnostics and therapy.Frontiers in bioengineering and biotechnology · 2026Review
- Pharmacological Treatment for Diabetic Macular Edema: A 2025 Update on Durability and Multi-Target Therapies.Drug design, development and therapy · 2026Review
- Adjuvant Anti-VEGF in Vitrectomy for Proliferative Diabetic Retinopathy: Current Evidence, Timing Considerations, and Clinical Implications.Current ophthalmology reports · 2026Article
- Comparative analysis of bevacizumab and sorafenib on the survival of retinal ganglion cells in the treatment of retinal diseases.Scientific reports · 2025Article
- Off-label use of Avastin in Pakistan: Lessons from the 2023 Punjab outbreak.Journal of public health research · 2025Article
- Article
- Efficacy, Safety and Immunogenicity of Sun's Ranibizumab Biosimilar in Neovascular Age-Related Macular Degeneration: A Phase 3, Double-Blind Comparative Study.Ophthalmology and therapy · 2024Article
- Next generation therapeutics for retinal neurodegenerative diseases.Journal of controlled release : official journal of the Controlled Release Society · 2024Review
- Intravitreal Anti-Vascular Endothelial Growth Factor Therapies for Retinal Disorders.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Targeting angiogenesis in oncology, ophthalmology and beyond.Nature reviews. Drug discovery · 2023Review
- Biosimilar versus InnovAtor MoLecule of RAnibizumab in Neovascular Age-Related MaCular DEgeneration (The BALANCE Trial): Real-World Evidence.Clinical ophthalmology (Auckland, N.Z.) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bevacizumab is a full-length, humanized monoclonal antibody directed against all the biologically active isoforms of vascular endothelial growth factor (VEGF-A). The antibody was initially designed and studied as an anti-angiogenic strategy to treat a variety of solid tumors. After approval by the US Food and Drug Administration, bevacizumab gained access into ophthalmology to treat various types of neovascular diseases. Since the first report in 2005 more than 100 publications share the experience with bevacizumab in ophthalmology. Two authors independently assessed the research results from Pubmed to April 2007. The reference list is a selection of key publications related to the issue. Currently, there is no well-designed randomized controlled trial yet to establish the efficacy and safety of intraocular bevacizumab for any ocular disease in spite of its assumed characteristics representing the most cost-effective VEGF inhibitor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.